噻托溴铵治疗慢性阻塞性肺疾病急性加重期的疗效及安全性观察

Clinical Effect and Safety of Tiotropium Bromide for the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的探讨噻托溴铵治疗慢性阻塞性肺疾病(COPD)急性加重期患者的临床疗效和安全性。方法选取我院2011年1月至2014年12月确诊为COPD急性加重期的患者200例为研究对象,随机分为两组各100例,对照组给予常规药物治疗,观察组在常规药物治疗基础上加用噻托溴铵粉雾剂治疗,比较两组的肺功能指标、动脉血气分析指标和不良反应。结果治疗28d及56 d,观察组的FEV1、FVC均显著高于治疗前(P<0.05),对照组的FEV1、FVC与治疗前无统计学差异(P>0.05)。治疗28 d及56 d,两组的Pa CO2均显著低于治疗前,Pa O2均显著高于治疗前(P<0.05)。两组的不良反应发生率无统计学差异(P>0.05)。结论噻托溴铵治疗COPD急性加重期患者的疗效显著,安全性高,能明显提高患者的肺功能,改善患者的临床症状。

Objective To explore the clinical effect of tiotropium bromide for the treatment of acute exacerbation of chronic obstructive pulmonary disease （COPD）. Methods A total of 200 cases of patients with acute exacerbation of COPD in our hospital from January 2011 to December 2014 were selected and randomly divided into two groups, with 100 cases in each group. The control group received routine drug therapy, while the observation group received tiotropium bromide inhalation powder on the basis of routine therapy. The pulmonary function, arterial blood gas analysis and adverse reactions were compared between two groups. Results At 28 days and 56 days of treatment, the FEV1 and FVC levels of observation group were significantly higher than those before treatment （P 〈0.05）, while the FEV1 and FVC levels of control group had no statistical change （P〉0.05）; The PaCO2 levels of both groups decreased significantly （P〈0.05）, and the PaO2 levels of both groups increased significantly （P〈0.05）. No statistical difference was found between two groups in the incidence of adverse reactions （P 〉0.05）. Conclusions Tiotropium bromide has significant efficacy and high safety for the treatment of acute exacerbation of COPD, which can obviously improve patients＇ pulmonary function and clinical symptoms.